The latest price target for Monopar Therapeutics (NASDAQ:MNPR) was reported by Chardan Capital on March 30, 2026. The analyst firm set a price target for $100.00 expecting MNPR to rise to within 12 months (a possible 86.53% upside). 28 analyst firms have reported ratings in the last year.

The latest analyst rating for Monopar Therapeutics (NASDAQ:MNPR) was provided by Chardan Capital, and Monopar Therapeutics maintained their buy rating.

The last upgrade for Monopar Therapeutics Inc happened on April 11, 2024 when JonesTrading raised their price target to $2. JonesTrading previously had a hold for Monopar Therapeutics Inc.

The last downgrade for Monopar Therapeutics Inc happened on November 14, 2025 when Raymond James changed their price target from $142 to $123 for Monopar Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Monopar Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Monopar Therapeutics was filed on March 30, 2026 so you should expect the next rating to be made available sometime around March 30, 2027.

While ratings are subjective and will change, the latest Monopar Therapeutics (MNPR) rating was a maintained with a price target of $100.00 to $100.00. The current price Monopar Therapeutics (MNPR) is trading at is $53.61, which is out of the analyst’s predicted range.